• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·ROG.SW
Share

Roche Holding AG Stocks

CHF 318Last Updated 02.04.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CHF 320.93B

CHF 318
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

28.08.2026 20:58

BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?

20.12.2025 03:43

Nine major pharma companies have made deals with Trump to lower drug prices

18.12.2025 01:30

U.S. to reach drug pricing agreements with Novartis and Roche - Bloomberg

25.11.2025 18:43

Oncology drugmaker Olema triples in a week after latest Roche data eases sector risks

18.11.2025 15:28

"Signal to sell": global stocks fall amid investor fatigue and cache shortages

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of ROG.SW is 380 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.09.2026 17:31

A hedge fund with a 235% return viewed the drop in gold prices as temporary

25.09.2026 17:11

Romania borrowed $600 million from the public through the "blood-for-bonds" program

25.09.2026 16:45

Western, Barbie, and Alpine Skiing: What Will Help Wrangler's Stock Rise 50%?

25.09.2026 16:11

Shares of CareDx, a medical test developer, soared to a 5-year high. Why?

25.09.2026 15:45

"Hacker Club" Incidents: How Errors in AI Tests Created New Risks for Investors

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026